| Name |
Targets |
Phase |
Company |
| pan-JAKs inhibitors |
|
|
|
| Ruxolitinib / INCB-18424, INC-424 |
JAK1, JAK2, JAK3 |
2011 Filed |
Incyte |
| Tasocitinib / tofacitinib, CP-690550 |
JAK1, JAK2, TYK2 |
2012 Filed |
Pfizer |
| Baricitinib/ INCB-28050, LY-3009104 |
JAK1, JAK2 |
Phase III |
Incyte |
| GLPG-0634 |
JAK1, JAK2 |
Phase II |
Galapagos |
| CYT-387 |
JAK1, JAK2, TYK2 |
Phase II |
Cytopia |
| AT-9283 |
JAK2, JAK3, BCR-ABL |
Phase II |
Astex |
| INCB-16562 |
JAK1, JAK2 |
Preclinical |
Incyte |
| Selective JAK2 inhibitors |
|
|
|
| Pacritinib/ SB-1518 |
JAK2/FLT3 |
Phase III |
S*Bio |
| Lestaurtinib / CEP-701 |
JAK2/PDGFR |
Phase III |
Caephalon |
| AZD-1480 |
JAK2 |
Phase II |
AstraZeneca |
| SAR-302503/ TG-101348 |
JAK2/RET |
Phase II |
Sanofi-Aventis |
| LY-2784544 |
JAK2 |
Phase II |
Lilly |
| BMS-911453 |
JAK2 |
Phase I |
Bristol-Myers Squibb |
| NS-018 |
JAK2 |
Phase I |
Nippon Shinyaku |
| TG02/ SB-1317 |
JAK2/CDK, FLT3 |
Phase I |
S*Bio |
| SB-1578 |
JAK2/FLT3 |
Phase I |
S*Bio |
| XL-019 |
JAK2 |
Phase I
(Termination) |
Exelixis |
| AG-490 |
JAK2 |
Tools
compounds |
No company |
| Selective JAK3 inhibitors |
|
|
|
| R-348 |
JAK3 |
Phase I |
Rigel |
| VX-509 |
JAK3 |
Phase I |
Vertex |
| NC-1153 |
JAK3 |
Preclinical |
Texas Uni. |
|